

Ludovic Martinet (Inserm DR2) obtained his PHD in 2008 at the University of Toulouse. After two post-doctoral trainings at IPBS (Toulouse, France) and QIMR Berghofer (Brisbane Australia) with famous leaders in oncoimmunology, he was recruited as Inserm CR1 in 2015 at the Cancer Research Center of Toulouse (CRCT, France). Since then, he develops a research axis dedicated to the understanding of the immune parameters impacting multiple myeloma development, in order to propose novel immune based therapeutic approaches. The quality of his research was evidenced by publications in high impact journals (JCI 2015, Cancer Cell 2018, Blood 2018,2022, Immunity 2020, 2023) and the Team#13 of the CRCT, that he co-lead with Pr Avet-Loiseau since 2019 (<https://www.crct-insERM.fr/13-h-avet-loiseau/>) was recently ranked “Outstanding” by the scientific advisory board and the HCERES.